Post by: Colleen Parr Dekker
- Second Quarter 2023 Financial Results
- Revenue of $1,057 million, impacted by an estimated $90-$110 million of revenue related to customer purchasing shifted from the second quarter into the first as a result of ERP system commercial ordering blackout period for legacy Bayer Animal Health products in April
- Reported Net Loss of $(97) million, Adjusted Net Income of $90 million
- Adjusted EBITDA of $222 million or 21.0% of Revenue
- Reported EPS of $(0.20), Adjusted EPS of $0.18
- Net leverage ratio of 5.9x Adjusted EBITDA
- Raising full year 2023 guidance ranges to reflect current assumptions:
- Revenue of $4,350 to $4,410 million
- Reported Net Loss of $127 to $170 million, Reported diluted EPS of $(0.34) to $(0.26)
- Adjusted EPS of $0.80 to $0.89, Adjusted EBITDA of $950 to $1,010 million
- Net leverage ratio expected at 5.5x to 5.8x Adjusted EBITDA at year-end 2023
- Announced the Environmental Protection Agency (EPA) completed its review of Seresto®, confirming continued registration
GREENFIELD, Ind (August 7, 2023) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2023, provided guidance for the third quarter of 2023, and raised guidance for the full year 2023.
